Phase II trial of 10 deaza-aminopterin in patients with bladder cancer Journal Article

  


Authors: Ahmed, T.; Yagoda, A.; Scher, H. I.; Sternberg, C.; Watson, R. C.
Article Title: Phase II trial of 10 deaza-aminopterin in patients with bladder cancer
Abstract: Deaza-aminopterin is a folate analog which is transported more rapidly than methotrexate into cells and appears to be more active than methotrexate against human and animal tumor in vitro. Fifteen patients with advanced urothelial tract cancer were given deaza-aminopterin 30-37.5 mg/m2 IV QW. In responding patients drug was given QOW after 4-6 consecutive doses. Doses were escalated or de-escalated by 7.5 mg/m2 depending on toxicity. Twelve patients had received prior chemotherapy which included methotrexate in nine. Three patients achieved a partial remission lasting 1, 3, and 3 months respectively: all responders had previously failed methotrexate after an initial response to a methotrexate containing regimen. None of the six patients who were methotrexate naive responded to deaza-aminopterin; 3 subsequently received methotrexate without response. Mild mucositis was universal and in 5 was severe. Six patients had an increase in liver transaminases probably secondary to anti-folate hepatotoxicity. Other toxicities included diarrhea, nausea, skin rash and fever. Further studies are needed to define the precise efficacy of deaza-aminopterin in patients with urothelial tract cancers. © 1986 Martinus Nijhoff Publishers.
Keywords: cancer chemotherapy; clinical article; aged; middle aged; diarrhea; drug efficacy; skin toxicity; antineoplastic agents; methotrexate; liver toxicity; phase 2 clinical trial; mucosa inflammation; nausea; urinary bladder neoplasms; alanine aminotransferase blood level; aspartate aminotransferase blood level; fever; rash; gastrointestinal toxicity; drug toxicity; drug dose; drug therapy; carcinoma, transitional cell; bladder carcinoma; adverse drug reaction; therapy; aminopterin; bladder; drug evaluation; 10 deazaaminopterin; intoxication; new drug; humans; human; male; female; priority journal
Journal Title: Investigational New Drugs
Volume: 4
Issue: 2
ISSN: 0167-6997
Publisher: Springer  
Date Published: 1986-06-01
Start Page: 171
End Page: 174
Language: English
DOI: 10.1007/bf00194598
PUBMED: 3733377
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022512632&doi=10.1007%2fBF00194598&partnerID=40&md5=d05a5a9032c3d26e34ffac9d4cfe94d4
Notes: Article -- Export Date: 18 August 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1130 Scher
  2. Cora N. Sternberg
    36 Sternberg
  3. Alan Yagoda
    51 Yagoda
  4. Robin Caird Watson
    25 Caird Watson
Related MSK Work